Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-22
2008-11-25
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S143000, C546S122000, C514S300000, C514S248000, C514S235200, C514S217070, C544S229000, C544S237000, C544S236000, C544S128000, C544S166000, C540S597000, C540S604000
Reexamination Certificate
active
07456195
ABSTRACT:
The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV):or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.
REFERENCES:
patent: 5475106 (1995-12-01), Bourzat et al.
patent: 6140353 (2000-10-01), Ackermann et al.
patent: 6194409 (2001-02-01), van Boeckel et al.
patent: 6242644 (2001-06-01), Ackermann et al.
patent: 6358960 (2002-03-01), Senokuchi et al.
patent: 6472393 (2002-10-01), Aliagas-Martin et al.
patent: 6500803 (2002-12-01), Klingler et al.
patent: 6548694 (2003-04-01), Alig et al.
patent: 6642252 (2003-11-01), Bisacchi et al.
patent: 6642386 (2003-11-01), Alig et al.
patent: 6699994 (2004-03-01), Babu et al.
patent: 7144895 (2006-12-01), Bisacchi et al.
patent: 2004/0176375 (2004-09-01), Bisacchi et al.
patent: 2004/0204412 (2004-10-01), Glunz et al.
patent: 2004/0235828 (2004-11-01), Dorsch et al.
patent: 2005/0130975 (2005-06-01), Barbeau
patent: 2005/0176760 (2005-08-01), Cezanne et al.
patent: 2006/0166997 (2006-07-01), Zhang et al.
patent: 2006/0211720 (2006-09-01), Glunz et al.
patent: 2007/0078155 (2007-04-01), Jaeschke et al.
patent: 2007/0135479 (2007-06-01), Ray
patent: WO02/057236 (2002-07-01), None
patent: WO 03/013531 (2003-02-01), None
patent: WO03/013531 (2003-02-01), None
patent: WO 03/084533 (2003-10-01), None
patent: WO2004/072101 (2004-08-01), None
patent: WO 2004/072102 (2004-08-01), None
patent: WO2004/072102 (2004-08-01), None
U.S. Appl. No. 11/328,479, Zhang et al.
Carson, S.D. et al., “The role of tissue factor in the production of thrombin”,Blood Coagulation and Fibrinolysis, vol. 4, pp. 281-292 (1993).
Colman, R.W., Chapter 6: “Contact Activation Pathway: Imflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities”,Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4thEd., Lippincott Williams & Wilkins, publ., Colman, R.W. et al., eds., pp. 103-121 (2001).
Morrissey, J.H., “Quantitation of activated Factor VII Levels in Plasma Using a Tissue Factor Mutant Selectively Deficient in Promoting Factor VII Activation”,Blood, vol. 81, No. 3, 1993: pp. 734-744.
Goodnight, S.H. et al., Chapter 4: “Screening Tests of Hemostasis”,Disorders of Hemostasis and Thrombosis: A Clinical Guide, The McGraw-Hill Companies, publ., pp. 41-51 (2001).
Schmaier, A.H., Chapter 5: “Contact Activation”,Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4thEd., Lippincott Williams & Wilkins, publ., Colman, R.W. et al., eds., pp. 105-127 (2001).
Hoffman, M., “A cell-based model of coagulation and the role of factor Vlla”,Blood Reviews(2003) 17, S1-S5.
Himber, J. et al., “Inhibition of tissue factor limits the growth of venous thrombus in the rabbit”,Journal of Thrombosis and Haemostasis, 1: 889-895 (2003).
Morrissey, J.H., “Tissue factor: in at the start . . . and the finish?”,Journal of Thrombosis and Haemostatis, 1: 878-880 (2003).
Hirsh, J. et al., “New anticoagulants”,Blood, vol. 105, No. 2, 453-463 (2005).
Girard, T.J. et al., “The role of tissue factor/factor Vlla in the pathophysiology of acute thrombotic formation”,Curr. Opin. Pharmacol., 2001, 1, 159-163.
Lazarus, R.A. et al., Inhibitors of Tissue Factor*Factor Vlla for Anticoagulant Therapy,Current Medicinal Chemistry, 2004, 11, 2275-2290.
Szalony, J.A. et al., “Pharmacological Intervention at Disparate Sites in the Coagulation Cascade: Comparison of Anti-thrombotic Efficacy vs. Bleeding Propensity in a Rat Model of Acute Arterial Thrombosis”,Journal of Thrombosis and Thrombolysis14(2), 113-121, (2002).
Suleymanov, O.D., “Pharmacological Interruption of Acute Thrombus Formation with Minimal Hemorrhagic Complications by a Small Molecule Tissue Factor/Factor Vlla Inhibitor: Comparison to Factor Xa and Thrombin Inhibition in a Nonhuman Primate Thrombosis Model”,The Journal of Pharmacology and Experimental Therapeutics, vol. 306, pp. 1115-1121 (2003).
Young, W.B. et al. “Factor Vlla inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model”,Bioorganic&Medicinal Chemistry Letters16 (2006) 2037-2041.
Szalony, J.A. et al., “Administration of a small molecule tissue factor/Factor Vlla inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time”,Thrombosis Research112 (2003) 167-174.
Moons, A.M. et al., “Recombinant Nematode Anticoagulant Protein c2, an Inhibitor of the Tissue Factor/Factor Vlla Complex, in Patients Undergoing Elective Coronary Angioplasty”,Journal of the American College of Cardiology, vol. 41, No. 12, 2147-2153i (2003).
Lee, A. et al., “Dos-Response Study of Recombinant Factor Vlla/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement”,Circulation, 104, 74-78 (2001).
Frederick, R. et al., “Modulators of the Coagulation Cascade: Focus and Recent Advances in Inhibitors of Tissue Factor, Factor Vlla and their Complex”,Current Medicinal Chemistry, 12, 397-417 (2005).
Arnold, C.S., “The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor Vlla inhibitor”,Thrombosis Research117, 343-349, (2006).
Zbinden et al.,Design of selective phenylglycine amide tissue factor/factor Vlla inhibitorsBioorganic Medicinal Chemistry Letters, vol. 15, Feb. 1, 2005, pp. 817-822.
Nirschl Alexandra A.
Priestley Eldon Scott
Zhang Xiaojun
Zou Yan
Berch Mark L.
Bristol--Myers Squibb Company
Jaisle Cecilia M
Sun Jing G.
LandOfFree
Phenylglycinamide and pyridylglycinamide derivatives useful... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylglycinamide and pyridylglycinamide derivatives useful..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylglycinamide and pyridylglycinamide derivatives useful... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4049609